AroCell AB (publ) Stock price Nasdaq Stockholm
Equities
SE0003883990
Biotechnology & Medical Research
Sales 2023 * | 45.1M 4.24M | Sales 2024 * | 61M 5.73M | Capitalization | 85M 7.98M |
---|---|---|---|---|---|
Net income 2023 * | -57M -5.35M | Net income 2024 * | -51M -4.79M | EV / Sales 2023 * | 0.82 x |
Net cash position 2023 * | 48M 4.51M | Net cash position 2024 * | 36M 3.38M | EV / Sales 2024 * | 0.8 x |
P/E ratio 2023 * |
-0.18
x | P/E ratio 2024 * |
-1.85
x | Employees | - |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 56.52% |
Managers | Title | Age | Since |
---|---|---|---|
Anders Hultman
CEO | Chief Executive Officer | 50 | 18-11-30 |
Lars Jakobsson
DFI | Director of Finance/CFO | 67 | - |
Gustav Sten
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 21-12-31 | |
Director/Board Member | 63 | 21-04-30 | |
Clas Runnberg
BRD | Director/Board Member | 72 | 22-12-31 |
1st Jan change | Capi. | |
---|---|---|
+9.08% | 45.97B | |
+52.67% | 43.93B | |
+9.39% | 42.34B | |
-8.59% | 28.27B | |
+17.72% | 27.18B | |
-20.80% | 19.44B | |
+13.73% | 13.83B | |
+31.68% | 12.4B | |
+9.26% | 11.45B |